Mucinex Tablet, Extended Release
NDC Package 72854-001-50

11-digit billing NDC: 72854000150
Table of Contents
    1. Package Information
    2. Other Packages
    3. Frequently Asked Questions

Package Information

Mucinex (naproxen sodium, dextromethorphan hydrobromide, guaifenesin) tablets is uses ■ helps loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus and make coughs more productive ■ temporarily relieves: ■ cough due to minor throat and bronchial irritation as may occur with the common cold or inhaled irritants ■ the intensity of coughing ■ the impulse to cough to help you get to sleep ■ minor aches and pains due to headache and the common cold ■ temporarily reduces fever. This formulation utilizes a tablet, extended release delivery system. Marketed by Reckitt Benckiser Llc, this product is identified by NDC 72854-001 and is authorized under FDA application NDA217338.

Identification & Billing

NDC Package Code
72854-001-50
Package Description
5 BLISTER PACK in 1 CARTON / 10 TABLET, EXTENDED RELEASE in 1 BLISTER PACK
Product Code
72854-001
11-Digit Billing Format
72854000150
RxNorm Crosswalk
  • RxCUI: 2744506 - dextromethorphan hydrobromide 30 MG / guaiFENesin 600 MG / naproxen sodium 110 MG 12HR Extended Release Oral Tablet
  • RxCUI: 2744506 - 12 HR dextromethorphan hydrobromide 30 MG / guaifenesin 600 MG / naproxen sodium 110 MG Extended Release Oral Tablet
  • RxCUI: 2744506 - dextromethorphan hydrobromide 30 MG / guaifenesin 600 MG / naproxen sodium 110 MG 12 HR Extended Release Oral Tablet

Clinical Specifications

Proprietary Name
Mucinex 12hr Cold And Fever Multi-symptom
Non-Proprietary Name
Naproxen Sodium, Dextromethorphan Hydrobromide, Guaifenesin
Substance Name
Dextromethorphan Hydrobromide; Naproxen Sodium; Guaifenesin
Dosage Form
Tablet, Extended Release - A solid dosage form containing a drug which allows at least a reduction in dosing frequency as compared to that drug presented in conventional dosage form.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
Pharmacologic Class
Usage Information
Uses ■ helps loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus and make coughs more productive ■ temporarily relieves: ■ cough due to minor throat and bronchial irritation as may occur with the common cold or inhaled irritants ■ the intensity of coughing ■ the impulse to cough to help you get to sleep ■ minor aches and pains due to headache and the common cold ■ temporarily reduces fever

Regulatory & Marketing

Labeler Name
Reckitt Benckiser Llc
Product Type
Human Otc Drug
FDA Application #
NDA217338
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
06-01-2026
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (72854-001). Click a package code to view its specific billing and regulatory data.

72854-001-16
2 BLISTER PACK in 1 CARTON / 8 TABLET, EXTENDED RELEASE in 1 BLISTER PACK
72854-001-32
4 BLISTER PACK in 1 CARTON / 8 TABLET, EXTENDED RELEASE in 1 BLISTER PACK

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 72854-001-50 identifies a specific commercial package of 5 blister pack in 1 carton / 10 tablet, extended release in 1 blister pack of Mucinex 12hr Cold And Fever Multi-symptom, a human over the counter drug labeled by Reckitt Benckiser Llc. This tablet, extended release is formulated for oral use and contains dextromethorphan hydrobromide; naproxen sodium; guaifenesin as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Reckitt Benckiser Llc on June 01, 2026. The current certification is valid through December 31, 2027.

How is this Reckitt Benckiser Llc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 72854000150. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
72854-001-50
11-Digit CMS (5-4-2)
72854-0001-50

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.